October 10 highlight and commentary: Triptan and ergotamine overuse in patients with headache at risk for vasoconstrictive complications

Neurology

Volumn 67, Issue 7, 2006, Pages 1111-

  Obermann, Mark ^a   Katsarava, Zaza ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ERGOT DERIVATIVE; ERGOTAMINE; OPIATE DERIVATIVE; TRIPTAN DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG INDUCED HEADACHE; DRUG SAFETY; HEADACHE; HUMAN; MIGRAINE; NOTE; PRIORITY JOURNAL; RISK FACTOR; TENSION HEADACHE; VASOCONSTRICTION;

EID: 33749834990     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000243634.66567.2e     Document Type: Note

References (3)

1. Limmroth V, Katsarava Z. Medication overuse headache. Curr Opin Neurol 2004;17:301-306.
2. Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology 2006;66:193-197.
3. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-568.